Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study.
Xi Zhong,Tingxuan Huang,Yulu Peng,Cheoklong NG,Xuhao Liu,Taile Jing,Wensu Wei,Zhiling Zhang,Hui Han,Minfeng Chen,Liru He,Jiwei Huang,Pei Dong
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e16519
IF: 45.3
2024-06-01
Journal of Clinical Oncology
Abstract:e16519 Background: The combination of immune checkpoint inhibitor (ICI) and tyrosine kinase inhibitor (TKI) has emerged as the standard first-line therapy for metastatic renal cell carcinoma (mRCC), however, limited clinical trials have investigated the role of ICI plus TKI in the treatment of metastatic non-clear cell renal carcinoma (mnccRCC) for its heterogeneity and low incidence. Our study presents multiple center real-world data with the optimal sample size so far to assess the efficacy and safety profile of ICI plus TKI in patients with mnccRCC. Methods: We performed a retrospective analysis including patients previously untreated with mnccRCC receiving TKI plus ICI or TKI in four institutions participated in this study. The primary endpoint was progression-free survival (PFS) according to the Response Evaluation Criteria in Solid Tumors version 1.1, others including overall survival (OS), the objective response rate (ORR) and treatment related adverse events (AEs). Results: A total of 214 patients were included for this study with 122 patients receiving TKI monotherapy and 92 patients receiving TKI plus ICI. Median follow-up time was 29.4 months (IQ1-IQ3, 15.7-48.5). The median age of patients was 49 years, with the majority being male (70.6%) and intermediate/poor risk. The most prevalent pathological subtype of nccRCC was papillary RCC (44.4%), followed by MIT family translocated RCC (16.4%), fumarate hydratase RCC (10.3%), chromophobe RCC (9.3%), other nccRCC (6.5%), and unclassified RCC (13.1%). The median PFS of the TKI monotherapy group and the TKI plus ICI combination group were 5.9 months (95%[CI], 4.3-7.5) versus 15.2 months (95%CI, 6.6-23.7), while mOS was 38.5 months (IQ1-IQ3=17.1-70.0) for TKI cohort and unreached (IQ1-IQ3=23.4-N) in TKI plus ICI cohort. The ORR and disease control rate (DCR) was 16.4% versus 29.4% and 48.4% versus 78.3% in the two cohorts. Any grade of AEs was 93.44% and 96.74% occurred in the monotherapy group and combination therapy group, while the incidence of grade ≥3 AEs was 23.77% and 35.87%, respectively. Conclusions: The findings from our retrospective real-world cohort of mnccRCC patients demonstrate that the combination of ICI plus TKI could significantly enhance PFS, ORR and OS compared to TKI monotherapy and no new safety signals were found. [Table: see text]
oncology